Boehringer’s Next Obesity Bet Not Just Another Incretin, It’s One of the Brain’s Most Powerful Hunger Pathways

Over the past few years, we’ve watched obesity medicines evolve from our favorite GLP-1 therapies we discuss like semaglutide, or dual agonists like tirzepatide, and now to triple agonists like retatrutide.